Business Overview and Summary of Significant Accounting Policies - Narrative (Details)	12 Months Ended
	Dec. 31, 2023 USD ($) segment product	Dec. 31, 2022 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of products approved by the U.S. FDA | product	11
Number of business segments | segment	1
Provision for doubtful accounts	$ 0	$ 0
Allowance for doubtful accounts receivable, current	$ 0	$ 0
Two Individual Customers | Customer concentration risk | Accounts receivable
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk, percentage	83.00%	86.00%